ponezumab
mAbexperimental
Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease. — Wikipedia
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00455000)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinBINDING AGENT
Beta amyloid A4 protein binding agent
Amyloid clearing function.
Binds free carboxy terminal amino acids 30-40 of the Abeta40 peptide (PMID:22197375).
APP other
Amyloid clearing function.
Binds free carboxy terminal amino acids 30-40 of the Abeta40 peptide (PMID:22197375).
- Beta amyloid A4 proteinImmunity, passive
APP immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPonezumab ↗
- ChEMBLCHEMBL1743058 ↗
Also known as
- pf-04360365
- pf-04360365
- pf-04360365
- ponezumab
- ponezumab
- ponezumab
- rn-1219
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01821118 | Phase 2 | Jun 1, 2013 | Pfizer |
| NCT01125631 | Phase 1 | May 1, 2010 | Pfizer |
| NCT01005862 | Phase 1 | Mar 1, 2010 | Pfizer |
| NCT00945672 | Phase 2 | Aug 1, 2009 | Pfizer |
| NCT00722046 | Phase 2 | Dec 1, 2008 | Pfizer |
| NCT00733642 | Phase 1 | Aug 1, 2008 | Pfizer |
| NCT00607308 | Phase 1 | Feb 1, 2008 | Pfizer |
| NCT00455000 | Phase 1 | Mar 1, 2007 | Pfizer |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 8 | 8 | 2 | 2007 |
1 organizations
Page 1 / 1